Table 1

Nonhematologic cancer incidence in 733 MPN patients, overall and by specific site*; number of observed and expected cases, relative risks as estimated by standardized incidence ratios (SIR) and 95% confidence intervals (1980-2006 period).

Any MPNCancer siteICD IXObserved†Expected‡SIR§95% CI
 Digestive system 150-159 10 15.08 0.63 0.33-1.16 
     Stomach 151 4 3.41 1.11 0.42-2.85 
     Colon & Rectum 153-154 5 7.75 0.61 0.25-1.46 
 Respiratory system 160-165 7 7.73 0.86 0.41-1.80 
     Lung 162 6 6.68 0.85 0.38-1.90 
 Melanoma 172 4 1.03 3.69 1.39-9.64 
 Skin (non-melanoma) 173 9 9.06 1.03 0.56-1.92 
 Breast 174 5 5.96 0.79 0.33-1.90 
 Prostate 185 4 5.56 0.68 0.25-1.80 
 Bladder 188 3 2.46 1.15 0.37-3.58 
 Kidney and other urinary organs 189 2 1.67 1.12 0.28-4.48 
 All cancer sites‖ 140-199 49 56.62 0.87 0.64-1.14 
Any MPNCancer siteICD IXObserved†Expected‡SIR§95% CI
 Digestive system 150-159 10 15.08 0.63 0.33-1.16 
     Stomach 151 4 3.41 1.11 0.42-2.85 
     Colon & Rectum 153-154 5 7.75 0.61 0.25-1.46 
 Respiratory system 160-165 7 7.73 0.86 0.41-1.80 
     Lung 162 6 6.68 0.85 0.38-1.90 
 Melanoma 172 4 1.03 3.69 1.39-9.64 
 Skin (non-melanoma) 173 9 9.06 1.03 0.56-1.92 
 Breast 174 5 5.96 0.79 0.33-1.90 
 Prostate 185 4 5.56 0.68 0.25-1.80 
 Bladder 188 3 2.46 1.15 0.37-3.58 
 Kidney and other urinary organs 189 2 1.67 1.12 0.28-4.48 
 All cancer sites‖ 140-199 49 56.62 0.87 0.64-1.14 
PVCancer siteICD IXObserved†Expected‡SIR§95% CI
 Digestive system 150-159 6 7.26 0.83 0.37-1.84 
     Colon & Rectum 153-154 4 3.70 1.08 0.41-2.88 
 Respiratory system 160-165 3 4.23 0.71 0.23-2.20 
     Lung 162 3 3.63 0.83 0.27-2.56 
 Melanoma 172 2 0.47 4.26 1.06-17.04 
 Skin (non-melanoma) 173 6 4.33 1.38 0.62-3.08 
 Prostate 185 2 3.18 0.63 0.16-2.52 
 Bladder 188 3 1.33 2.25 0.73-6.98 
 Kidney and other urinary organs 189 2 0.68 2.96 0.74-11.84 
 All cancer sites‖ 140-199 26 26.98 0.96 0.63-1.41 
PVCancer siteICD IXObserved†Expected‡SIR§95% CI
 Digestive system 150-159 6 7.26 0.83 0.37-1.84 
     Colon & Rectum 153-154 4 3.70 1.08 0.41-2.88 
 Respiratory system 160-165 3 4.23 0.71 0.23-2.20 
     Lung 162 3 3.63 0.83 0.27-2.56 
 Melanoma 172 2 0.47 4.26 1.06-17.04 
 Skin (non-melanoma) 173 6 4.33 1.38 0.62-3.08 
 Prostate 185 2 3.18 0.63 0.16-2.52 
 Bladder 188 3 1.33 2.25 0.73-6.98 
 Kidney and other urinary organs 189 2 0.68 2.96 0.74-11.84 
 All cancer sites‖ 140-199 26 26.98 0.96 0.63-1.41 
ETCancer siteICD IXObserved†Expected‡SIR§95% CI
 Digestive system 150-159 3 6.90 0.43 0.14-1.35 
     Stomach 151 2 1.53 1.30 0.33-5.23 
 Respiratory system 160-165 4 2.91 1.37 0.52-3.66 
     Lung 162 3 2.54 1.18 0.38-3.67 
 Skin (non-melanoma) 173 3 4.14 0.72 0.23-2.25 
 Breast 174 5 3.95 1.26 0.52-3.04 
 Prostate 185 2 1.85 1.08 0.27-4.33 
 All cancer sites‖ 140-199 22 26.22 0.84 0.53-1.27 
ETCancer siteICD IXObserved†Expected‡SIR§95% CI
 Digestive system 150-159 3 6.90 0.43 0.14-1.35 
     Stomach 151 2 1.53 1.30 0.33-5.23 
 Respiratory system 160-165 4 2.91 1.37 0.52-3.66 
     Lung 162 3 2.54 1.18 0.38-3.67 
 Skin (non-melanoma) 173 3 4.14 0.72 0.23-2.25 
 Breast 174 5 3.95 1.26 0.52-3.04 
 Prostate 185 2 1.85 1.08 0.27-4.33 
 All cancer sites‖ 140-199 22 26.22 0.84 0.53-1.27 
*

Only cancer sites with at least 2 observed cases.

†

Cases of cancer newly diagnosed in MPN patients.

‡

Expected cases of cancer according to incidence rates in the general population of the area applied to the number of person years in the study follow up.

§

Standardized incidence ratio, obtained from the ratio of Observed to Expected cases ‖ except lymphoproliferative neoplasm

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal